Pregabalin
Used to relieve nerve pain caused by conditions such as diabetic neuropathy, shingles, fibromyalgia, and spinal cord injury, and also used as an add-on treatment to control certain types of seizures in epilepsy. It works by reducing abnormal electrical activity in the nervous system that causes pain and seizures.
分子量
159.2260 g/mol
LogP
-1.60
TPSA
63.30 Ų
リピンスキーの五則
適合
治療領域
薬物分類
作用機序
Binds alpha-2-delta subunit of voltage-gated calcium channels.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds alpha-2-delta subunit of voltage-gated calcium channels.
2D構造
Cite this structure
Embed this structure
SMILES
CC(C)C[C@H](CN)CC(=O)O
InChI
InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
Molecular Formula
C8H17NO2
HBD / HBA
2 / 3
回転可能結合数
5
重原子数
11
Pregabalin potentiates the respiratory depressant and sedative effects of morphine, creating a high-risk combination for overdose.
Pregabalin combined with oxycodone produces synergistic respiratory and CNS depression, substantially elevating overdose risk.
Duloxetine and pregabalin are commonly co-prescribed for neuropathic pain with complementary mechanisms; additive CNS effects including dizziness, somnolence, and cognitive impairment can occur.
Omeprazole does not have a pharmacokinetic interaction with pregabalin since pregabalin is not CYP-metabolised; however, both can cause peripheral oedema through independent mechanisms, producing additive fluid retention.
Combining gabapentin and pregabalin, two alpha-2-delta ligands with similar mechanisms, produces additive CNS depression and dose-dependent adverse effects including respiratory depression, dizziness, and somnolence.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Used to relieve nerve pain caused by conditions such as diabetic neuropathy, shingles, fibromyalgia, and spinal cord injury, and also used as an add-on treatment to control certain types of seizures in epilepsy. It works by reducing abnormal electrical activity in the nervous system that causes pain and seizures.
Binds alpha-2-delta subunit of voltage-gated calcium channels.
Key pharmacokinetic parameters for Pregabalin: Half-life: 6.3 hours.
Yes, Pregabalin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1059. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5486971. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pregabalin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pregabalin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pregabalin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pregabalin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pregabalin"></drugfyi-drug>